Tagraxofusp

Generic Name
Tagraxofusp
Brand Names
Elzonris
Drug Type
Biotech
Chemical Formula
-
CAS Number
2055491-00-2
Unique Ingredient Identifier
8ZHS5657EH
Background

Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in Escherichia coli. Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for ...

Indication

Tagraxofusp is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). In the US, it is approved for use in adults and pediatric patients over 2 years old. In Europe, it is only approved for use in adults.

Associated Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Associated Therapies
First-line Therapy
© Copyright 2024. All Rights Reserved by MedPath